Javlor for metastatic carcinoma of the urothelial tract

Pierre Fabre has launched Javlor (vinflunine) as monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a platinum-containing regimen.

Vinflunine is a vinca alkaloid agent, it acts mainly as a mitotic spindle poison to impair chromosomal segregation during mitosis.

Secondary analyses of a randomised clinical trial in patients with advanced or metastatic transitional cell carcinoma of the urothelium, as second line therapy after failure of a prior platinum containing regimen, confirmed the clinical efficacy of vinflunine compared to best standard of care alone.

The efficacy and safety of vinflunine have not been studied in patients with Performance Status ≥2.

As with all vinca alkaloids and analogues, vinflunine is fatal if given intrathecally. Only personnel trained in the use of vinca alkaloids and analogues should be involved in the management of patients with vinflunine.

View Javlor drug record

Further information: Pierre Fabre

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more